Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Josip Pasini is active.

Publication


Featured researches published by Josip Pasini.


Nephrology Dialysis Transplantation | 2014

Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy

Bojan Jelaković; Jovan Nikolic; Zoran Radovanović; Joëlle Nortier; Jean-Pierre Cosyns; Arthur P. Grollman; Nikolina Bašić-Jukić; Mladen Belicza; Danica Bukvić; Semra Čavaljuga; Dubravka Čvorišćec; Ante Cvitković; Živka Dika; Plamen Dimitrov; Ljubica Đukanović; Karen L. Edwards; Dušan Ferluga; Ljubica Fuštar-Preradović; Gheorghe Gluhovschi; Goran Imamović; Tratinčica Jakovina; Petar Kes; Ninoslav Leko; Zvonimir Medverec; Enisa Mesic; Marica Miletić-Medved; Frederick Miller; Nikola Pavlovic; Josip Pasini; Stjepko Pleština

Currently used diagnostic criteria in different endemic (Balkan) nephropathy (EN) centers involve different combinations of parameters, various cut-off values and many of them are not in agreement with proposed international guidelines. Leaders of EN centers began to address these problems at scientific meetings, and this paper is the outgrowth of those discussions. The main aim is to provide recommendations for clinical work on current knowledge and expertise. This document is developed for use by general physicians, nephrologists, urologist, public health experts and epidemiologist, and it is hoped that it will be adopted by responsible institutions in countries harboring EN. National medical providers should cover costs of screening and diagnostic procedures and treatment of EN patients with or without upper urothelial cancers.


Kidney & Blood Pressure Research | 2009

Immunolocalization and mRNA Expression of Bone Morphogenetic Protein-6 in Human Clear Cell Renal Carcinoma

Nikolina Bašić-Jukić; Margareta Radic-Antolic; Tvrtko Hudolin; Marijana Ćorić; Renata Zadro; Josip Pasini; Zeljko Kastelan; Petar Kes

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β superfamily of proteins. Dysregulation of BMP signaling has been suggested in the carcinogenesis of different organs. We determined BMP-6 mRNA and protein expression in localized human clear cell renal carcinoma (CCRC), obtained from 20 patients who underwent nephrectomy, by the real-time polymerase chain reaction and immunohistochemistry. 15/20 patients exhibited higher BMP-6 mRNA expression in malignant than in healthy renal tissue relative to the PBGD expression (p < 0.05). Immunostaining intensity for BMP-6 in healthy renal tissue ranged from 0 to 2 (average 0.9), as well as in renal clear cell carcinoma (average 1.1). Seven of 20 (35%) healthy tissue samples failed to stain with BMP-6 antibody, compared to 2/20 (10%) tumor samples (p < 0.05). BMP-6 immunostaining was positive in 18/20 CCRC samples. Staining was localized in the cytoplasm and/or membrane of malignant cells. Malignant tissue had significantly higher BMP-6 mRNA expression than healthy tissue. There was no significant correlation between BMP-6 mRNA and protein expression with disease presentation, disease progression and patients’ characteristics. Long-term follow-up of our patients is needed to determine the possible role of increased expression of BMP-6 in CCRC.


Journal of Nephrology | 2011

Bone morphogenetic protein-7 expression is down-regulated in human clear cell renal carcinoma

Nikolina Bašić-Jukić; Tvrtko Hudolin; Margareta Radic-Antolic; Marijana Ćorić; Renata Zadro; Zeljko Kastelan; Josip Pasini; Daniela Bandic-Pavlovic; Petar Kes

BACKGROUND Recent studies demonstrated that the expression pattern of bone morphogenetic protein-7 (BMP-7) is altered in different tumors. We determined expression of BMP-7 in human clear cell renal carcinoma (CCRC). METHODS Samples from cancer and corresponding healthy tissue were obtained from 20 patients who underwent nephrectomy for CCRC. Expression of BMP-7 mRNA was determined by reverse transcriptase polymerase chain reaction (RT-PCR), and protein expression was analyzed by immunohistochemistry. RESULTS RT-PCR showed strong down-regulation of BMP-7 mRNA in cancer tissue. Immunohistochemistry revealed expression of BMP-7 in normal renal tissue, with almost complete loss of BMP-7 expression in malignant cells of 6 patients (30%). After 3 years of follow-up, 5 out of 6 patients with high BMP-7 mRNA expression were alive and disease-free, compared with 9 out of 14 patients with low BMP-7 mRNA expression. CONCLUSIONS BMP-7 mRNA and protein expression were down-regulated in CCRC. Further prospective studies are needed to characterize the role of BMP-7 in human CCRC.


Radiology and Oncology | 2010

Ureteral metastasis as the first and sole manifestation of gastric cancer dissemination

Vesna Bišof; Antonio Juretić; Josip Pasini; Marijana Ćorić; Mislav Grgić; Marija Gamulin; Zoran Rakušić; Zdenko Krajina; Martina Bašić-Koretić; Ana Mišir; Ranka Štern-Padovan

Ureteral metastasis as the first and sole manifestation of gastric cancer dissemination Background. Isolated ureteral metastasis from gastric cancer is extremely rare. Case report. We describe a 50 year old man with a history of subtotal gastrectomy who presented 4 years later with an ureteral metastasis. He was asymptomatic and diagnostic tests were performed due to the elevated creatinine level disclosed incidentally. The partial resection of distal right ureter as well as the resection of the right ureterovesical junction was performed with the implantation of double J stent. Histopathology revealed a metastasis of the adenocarcinoma that matched perfectly a tumour specimen from the gastric cancer surgery. It was first and isolated manifestation of gastric cancer dissemination. Conclusions. Although rare, the ureteral metastasis from gastric cancer can be the first, sole and asymptomatic manifestation of gastric cancer dissemination after a period of time.


The Prostate | 2006

Immunohistochemical expression of tumor antigens MAGE‐A1, MAGE‐A3/4, and NY‐ESO‐1 in cancerous and benign prostatic tissue

Tvrtko Hudolin; Antonio Juretić; Giulio C. Spagnoli; Josip Pasini; Daniela Bandic; Michael Heberer; Miljenko Kosicek; Mirjana Čačić


Tumori | 2006

Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer.

Ivica Mokos; Jasminka Jakić-Razumović; Zvonimir Marekovic; Josip Pasini


Transplantation Proceedings | 2006

Conservative Surgical Treatment of Low-Grade Urothelial Carcinoma in the Renal Allograft Recipient: A Case Report

Ivica Mokos; Josip Pasini; Ranka Štern-Padovan; Sanja Mrsic; Suncica Ries


Urology | 2006

Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in squamous cell carcinoma of the penis

Tvrtko Hudolin; Antonio Juretić; Josip Pasini; Davor Tomas; Giulio C. Spagnoli; Michael Heberer; Jordan Dimanovski; Bozo Kruslin


Collegium Antropologicum | 2005

Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.

Marija M. Bernat; Josip Pasini; Zvonimir Marekovic


Acta Clinica Croatica | 2011

Transurethral incision/resection of the prostate (TUIP/TURP) in operative treatment of repeated bladder outlet obstruction early after kidney transplantation.

Ivica Mokos; Željko Kaštelan; Nikolina Bašić-Jukić; Petar Kes; Josip Pasini

Collaboration


Dive into the Josip Pasini's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Željko Kaštelan

University Hospital Centre Zagreb

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ivica Mokos

University Hospital Centre Zagreb

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge